A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study is to characterize the regimen limiting toxicities (RLT) and recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving remission induction chemotherapy with cytarabine and idarubicin.
Epistemonikos ID: 5cdc6e1881daea325cf55efa4d9ad5acc1f2cea8
First added on: May 17, 2024